NLS Pharmaceutics (NLSP) Competitors $1.98 -0.18 (-8.33%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.06 +0.08 (+3.79%) As of 07/25/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. CLNN, KZR, FGEN, BDRX, SNYR, MIRA, ESLA, DYAI, SCYX, and ENLVShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Clene (CLNN), Kezar Life Sciences (KZR), FibroGen (FGEN), Biodexa Pharmaceuticals (BDRX), Synergy CHC (SNYR), MIRA Pharmaceuticals (MIRA), Estrella Immunopharma (ESLA), Dyadic International (DYAI), SCYNEXIS (SCYX), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Its Competitors Clene Kezar Life Sciences FibroGen Biodexa Pharmaceuticals Synergy CHC MIRA Pharmaceuticals Estrella Immunopharma Dyadic International SCYNEXIS Enlivex Therapeutics NLS Pharmaceutics (NASDAQ:NLSP) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Do analysts rate NLSP or CLNN? Clene has a consensus target price of $40.00, indicating a potential upside of 995.89%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has higher earnings and valuation, NLSP or CLNN? NLS Pharmaceutics has higher earnings, but lower revenue than Clene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$1.98MN/AN/AClene$350K86.21-$39.40M-$4.04-0.90 Does the media favor NLSP or CLNN? In the previous week, Clene had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 2 mentions for Clene and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.87 beat Clene's score of 0.94 indicating that NLS Pharmaceutics is being referred to more favorably in the media. Company Overall Sentiment NLS Pharmaceutics Very Positive Clene Positive Do institutionals and insiders believe in NLSP or CLNN? 23.3% of Clene shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 35.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is NLSP or CLNN more profitable? NLS Pharmaceutics has a net margin of 0.00% compared to Clene's net margin of -8,306.00%. Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A Clene -8,306.00%N/A -105.11% Which has more volatility and risk, NLSP or CLNN? NLS Pharmaceutics has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. SummaryClene beats NLS Pharmaceutics on 9 of the 13 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.12M$2.49B$5.69B$9.50BDividend YieldN/A1.65%4.58%4.01%P/E RatioN/A9.0528.1020.05Price / SalesN/A612.51432.4490.07Price / CashN/A165.2136.2258.56Price / Book-5.355.168.665.87Net Income-$1.98M$30.99M$3.25B$258.55M7 Day Performance-10.81%7.74%4.23%3.74%1 Month Performance-22.05%16.27%10.52%11.75%1 Year Performance942.11%-1.88%34.41%18.03% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.98-8.3%N/A+909.2%$7.12MN/A0.006Positive NewsGap DownCLNNClene3.4621 of 5 stars$3.84+0.5%$40.00+941.9%-18.2%$31.86M$340K-0.95100KZRKezar Life Sciences4.1212 of 5 stars$4.34+0.8%$39.50+811.2%-34.5%$31.69M$7M-0.4060FGENFibroGen4.5953 of 5 stars$7.64+1.0%$250.00+3,174.4%-75.8%$31.20M$7.00M-3.09570Positive NewsBDRXBiodexa Pharmaceuticals0.2928 of 5 stars$0.87+2.5%N/AN/A$31.06M$470K0.0020Positive NewsSNYRSynergy CHC4.0745 of 5 stars$3.35-4.3%$10.00+198.5%N/A$30.80M$33.59M0.0040Gap DownMIRAMIRA Pharmaceuticals2.5957 of 5 stars$1.66-8.1%$14.00+745.9%-43.1%$30.45MN/A-3.212ESLAEstrella Immunopharma3.2141 of 5 stars$0.86+0.7%$16.00+1,762.6%-47.9%$30.38MN/A-3.23N/ANews CoverageGap DownDYAIDyadic International3.3012 of 5 stars$1.00+3.0%$6.00+498.2%-22.0%$30.18M$3.49M-5.017Gap UpSCYXSCYNEXIS0.8975 of 5 stars$0.72-0.8%N/A-65.0%$28.33M$3.75M-1.3060Positive NewsENLVEnlivex Therapeutics2.8033 of 5 stars$1.19flat$10.00+740.3%-19.3%$28.15MN/A-1.8070News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Clene Alternatives Kezar Life Sciences Alternatives FibroGen Alternatives Biodexa Pharmaceuticals Alternatives Synergy CHC Alternatives MIRA Pharmaceuticals Alternatives Estrella Immunopharma Alternatives Dyadic International Alternatives SCYNEXIS Alternatives Enlivex Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLSP Stock Alerts